Two Phase 4 studies, HARMONY IN DIVERSITY and HALO, found adults on GLP-1 medications for weight loss reported significant satisfaction improvements after receiving combined neurotoxin and hyaluronic acid (HA) injectable treatments. Participants noted better facial appearance, skin quality, and psychological and social function, with most adverse effects being mild. These findings highlight the potential for tailored aesthetic treatments to address facial changes linked to GLP-1 use, offering new options for patient care. Further research and presentations at ASDS 2026 will expand understanding of multimodal aesthetic therapies.
Allergan Aesthetics reports on facial satisfaction improvements with GLP-1 medications. For readers following the health sector, here is Pluang's market snapshot as of Nov 08, 2026 23:02 WIB: 88 of 150 US health stocks rose, 62 fell. Notable movers include ERAS at USD 14.41 (+8.59%), RVMD at USD 192.28 (+8.24%), and HIMS at USD 26.00 (+8.06%) with a typical hold time of 24 days and 86% sell order activity.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Moonbeam (GLMR) experienced a significant price increase of 10.52% within one hour, reaching $0.007898, which was also the highest price in the past 24 hours. Over the full day, GLMR gained 11.30%, with its price fluctuating between $0.007003 and $0....
